This week in pharmaceutical news, we saw important updates on vaccines, major deals in the industry, ambitious plans from China, and warnings from Europe’s largest drug companies about staying competitive.
**Vaccine Safety Reaffirmed by FDA Nominee**
Dr. Heidi Overton, former President Donald Trump’s pick to lead the U.S. Food and Drug Administration (FDA), has strongly supported the safety and effectiveness of the measles, mumps, and rubella (MMR) vaccine. During her Senate confirmation hearing, she called the vaccine “safe and effective,” emphasizing its critical role in combating measles outbreaks. This statement comes at a time when vaccine hesitancy continues to be a public health concern. The MMR vaccine is given in two doses—one at 12-15 months of age and another at 4-6 years—to protect against these serious diseases. Maintaining high vaccination rates is essential to prevent outbreaks, especially in communities where vaccination rates are low.
**Major Funding for AI-Discovered Medicines**
A biotech company called Enveda recently raised $311 million in a new funding round to advance therapies discovered using artificial intelligence (AI) and natural sources. This brings their total funding to over $845 million. The money will help move their therapies, which target inflammatory and metabolic disorders like diabetes and rheumatoid arthritis, further along in clinical trials. The research is led by experts in AI and healthcare, and the company aims to develop oral medications that could improve how these conditions are treated. AI is playing an increasingly important role in drug discovery by helping scientists identify new treatments faster and more efficiently.
**Europe’s Big Pharma Warns of Losing Ground**
The leaders of nine major European pharmaceutical companies, including AstraZeneca, Roche, and Novartis, have issued a warning about the continent’s declining competitiveness in the global drug industry. In an open letter to European governments, they stated that Europe is falling behind the United States and China, and urgent changes are needed to close this gap. They pointed out that Europe must improve its business environment, support innovation, and encourage investment to keep pace with faster-growing regions. Without improvements, they warned, the gap will only widen, potentially affecting jobs, research, and access to new medicines for patients.
**Novo Nordisk Aims for Major Growth by 2030**
Novo Nordisk, a leader in diabetes and obesity treatments, has announced ambitious goals for the next decade. The company plans to launch more than five blockbuster drugs (medications with annual sales over $1 billion each) by 2030. It also aims to achieve sales of over $23 billion (150 billion Danish kroner). The company shared these goals at its Capital Markets Day, where it outlined its strategy to expand its portfolio, particularly in the growing areas of obesity and metabolic diseases. However, investors have had a cautious response, likely due to the high costs and long timelines associated with developing new drugs.
**China’s Plan to Lead in Drug Innovation by 2030**
The Chinese government has revealed a bold five-year plan to strengthen its position as a global leader in drug innovation. By 2030, China aims to develop and manufacture 25% of the world’s first-in-class drugs—these are groundbreaking treatments that use new mechanisms to treat diseases. The plan marks a shift from China’s previous focus on producing generic or copycat drugs to a stronger emphasis on original, innovative research. Government ministries have outlined steps to support this goal, including increased funding for research, streamlining drug approval processes, and fostering collaboration between universities, research institutions, and pharmaceutical companies. Analysts believe this strategy will help China become a major player in the global pharmaceutical market.
**Big Pharma Deals and Partnerships**
This week also saw several significant deals in the pharmaceutical industry:
– **Eli Lilly and Company**, **Roche**, and **Telix Pharmaceuticals** all made moves to expand their product portfolios through acquisitions or partnerships.
– The deals highlight the industry’s focus on strengthening pipelines, especially in areas like cancer, rare diseases, and radiopharmaceuticals (treatments that use radioactive substances to target diseases).
**CPHI Milan 2026: A Must-Attend Event for Pharma Professionals**
The CPHI Milan 2026 event, taking place October 6-8, 2026, in Milan, Italy, is one of the largest gatherings of pharmaceutical professionals in the world. It brings together over 62,000 attendees from 166 countries, 2,900 exhibitors, and industry leaders to showcase the latest innovations in drug development, manufacturing, and packaging. Attendees will have the chance to attend conferences, network with experts, and explore cutting-edge technologies. The event will also feature a new **CPHI Sustainability Summit**, focusing on environmentally friendly practices in the pharmaceutical industry. Pharma professionals can save 10% on registration by using the code **REFG45791** at checkout.
**Podcast Spotlight: Sandoz’s Roadmap to Biosimilar Leadership**
Sandoz, a global leader in biosimilars (generic versions of biologic drugs), recently shared its strategy to become the top company in the field within the next decade. In a new podcast episode, Robert Barrie, editor at GlobalData Healthcare, spoke with Rebecca Guntern, Sandoz’s Chief Commercial Officer, about the company’s plan called **Bio100**. The plan includes targets to expand its biosimilar portfolio, improve market access, and use advanced targeting technology to engage with healthcare professionals and patients. Biosimilars play a crucial role in making biologic drugs more affordable and accessible to patients worldwide.